↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Lyon RA, Titeler M, Seggel MR, Glennon RA (January 1988). „Indolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogens”. European Journal of Pharmacology145 (3): 291–7. DOI:10.1016/0014-2999(88)90432-3. PMID3350047.
↑Peroutka SJ, McCarthy BG, Guan XM (1991). „5-benzyloxytryptamine: a relatively selective 5-hydroxytryptamine 1D/1B agent”. Life Sciences49 (6): 409–18. DOI:10.1016/0024-3205(91)90582-V. PMID1650872.
↑Cohen ML, Schenck K, Nelson D, Robertson DW (January 1992). „Sumatriptan and 5-benzyloxytryptamine: contractility of two 5-HT1D receptor ligands in canine saphenous veins”. European Journal of Pharmacology211 (1): 43–6. DOI:10.1016/0014-2999(92)90260-B. PMID1319907.
↑Boess FG, Monsma FJ, Carolo C, Meyer V, Rudler A, Zwingelstein C, Sleight AJ (1997). „Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells”. Neuropharmacology36 (4-5): 713–20. DOI:10.1016/S0028-3908(97)00019-1. PMID9225298.